COMP <GO>
SYRE vs LLY // 10Y YIELD & FRED MACRO BETA
Spyre Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SYRE 4
— LLY 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: SYRE
LAST: $96.56 (-2.43%) • MKT CAP: $10.33B
macro-sensitivity
0.89
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 83.64% | -39.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | 32.36% | -52.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | 2.30% | -3.94 | LLY | /fcf-yield <GO> |
| Operating Margin | 16.50% | 40.21% | -23.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 31.90% | -19.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 45.51% | -27.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | SYRE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.1 | 77.9 | -18.82 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.89 | 0.51 | +0.38 | SYRE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 26.3x | -4.25 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.33B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | LLY REV | SYRE GROSS % | LLY GROSS % | SYRE FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$169.3M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | -$157.4M | $8.82B |
| FY 2023 | $886.0K | $34.12B | 44.0% | 79.3% | -$99.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
LLY // BETA 0.51